Bacteria Patents (Class 530/825)
-
Patent number: 8287882Abstract: The use of flagellin and flagellin related polypectides for the protection of mammals from the effects of apoptsis is described.Type: GrantFiled: May 18, 2011Date of Patent: October 16, 2012Assignee: Cleveland Clinic FoundationInventors: Andrei V. Gudkov, Joseph A. DiDonato, Vadim Krivokrysenko
-
Patent number: 8273360Abstract: A composition comprising (a) Neisseria meningitidis serogroup B outer membrane vesicles (OMVs), and (b) an immunogenic component selected from other Neisseria proteins, or immunogenic fragments thereof. Component (b) preferably includes a protein from a different NmB strain from that from which the OMV of component (a) is derived. The OMVs are preferably obtained by deoxycholate extraction. Optionally, the composition may also comprise a protective antigen against other pathogens.Type: GrantFiled: January 17, 2001Date of Patent: September 25, 2012Assignee: Novartis AGInventors: Mariagrazia Pizza, Rino Rappuoli, Marzia Monica Giuliani
-
Patent number: 8187611Abstract: The present invention provides a purified peptide comprising at least one of the sequences LKQKSSNSRKKRSTS (SEQ ID NO:1), or VKNKRTFLSPWISNI (SEQ ID NO:2) as well as a vaccine, a method to protect or treat an animal from anthrax toxin, a method of making a vaccine and the use of the peptide. The present invention also provides a monoclonal antibody that specifically binds to a peptide sequence comprising at least one of the following peptide sequences: LKQKSSNSRKKRSTS (SEQ ID NO:1), or VKNKRTFLSPWISNI (SEQ ID NO:2) as well as a method to protect or treat an animal from anthrax toxin, a method of making a vaccine, a pharmaceutical composition, a method of making a pharmaceutical composition, and the use of the monoclonal antibody.Type: GrantFiled: October 5, 2010Date of Patent: May 29, 2012Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventors: Nareen Abboud, Arturo Casadevall
-
Patent number: 8119147Abstract: The present invention provides compositions including polypeptides having the characteristics of polypeptides expressed by a reference microbe such E. coli or Salmonella. Examples of Salmonella strains that can be used include, for instance, S. enterica serovar Newport, S. enterica serovar Enteritidis, S. enterica serovar Typhimurium, and S. enterica serovar Dublin. Also provided are compositions including polypeptides having a particular molecular weight and a mass fingerprint that includes polypeptide fragments having a particular set of masses, or polypeptides having an amino acid sequence with at least about 95% identity with an amino acid sequence, wherein the polypeptide has seroreactive activity. The present invention also provides methods of making and methods of using such compositions.Type: GrantFiled: September 20, 2004Date of Patent: February 21, 2012Assignee: Epitopix, LLCInventors: Daryll A. Emery, Darren E. Straub, Laura Wonderling
-
Patent number: 8101194Abstract: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.Type: GrantFiled: October 11, 2002Date of Patent: January 24, 2012Assignee: Wyeth LLCInventors: Gary W. Zlotnick, Leah Diane Fletcher, John Erwin Farley, Liesel A. Bernfield, Robert J. Zagursky, Benjamin J. Metcalf
-
Patent number: 8088894Abstract: The present invention provides a Mycoplasma pneumoniae community acquired respiratory distress syndrome (CARDS) toxin, biologically active fragments/domains of the CARDS toxin, antibodies to the CARDS toxin and nucleic acids encoding the CARDS toxin. Also provided are methods of diagnosing, treating and/or preventing infection by Mycoplasma pneumoniae using the compositions provided herein.Type: GrantFiled: November 4, 2009Date of Patent: January 3, 2012Assignee: Board of Regents, The University of Texas SystemInventors: Joel Barry Baseman, Thirumalai Rengasamy Kannan
-
Patent number: 8025891Abstract: The present invention features peptides of a PorB polypeptide, which PorB peptides are useful in production of antibodies that bind the full-length PorB polypeptide and as a therapeutic agent. In specific embodiments the invention features a composition comprising one or more PorB peptides (other than a full-length PorB polypeptide), which peptides contain at least one epitope that can elicit Chlamydia-neutralizing antibodies. The invention also features methods for induction of a protective immune response against infection by Chlamydia and Chlamydophila.Type: GrantFiled: January 13, 2010Date of Patent: September 27, 2011Assignee: The Regents of the University of CaliforniaInventors: Richard S. Stephens, Diane Kawa
-
Patent number: 8025885Abstract: The present invention provides isolated polypeptides isolatable from a Staphylococcus spp. Also provided by the present invention are compositions that include one or more of the polypeptides, and methods for making and methods for using the polypeptides.Type: GrantFiled: September 11, 2006Date of Patent: September 27, 2011Assignee: Epitopix, LLCInventors: Daryll A. Emery, Darren E. Straub, Laura Wonderling, Lisa L. Herron Olson
-
Patent number: 8017741Abstract: The present invention relates to a toxin comprising a modified light chain of a botulinum toxin type E, wherein the modified light chain comprises amino acid sequence PFVNKQFN (SEQ ID NO: 120) at the N-terminus, and amino acid sequence xDxxxLL (SEQ ID NO: 111) at the C-terminus, wherein x is any amino acid.Type: GrantFiled: January 8, 2010Date of Patent: September 13, 2011Inventors: Ester Fernandez-Salas, Lance E. Steward, Todd Herrington, K. Roger Aoki
-
Patent number: 8017134Abstract: A single polypeptide is provided which comprises first and second domains. The first domain enables the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis, and the second domain enables the polypeptide to be translocated into a target cell or increases the solubility of the polypeptide, or both. The polypeptide thus combines useful properties of a clostridial toxin, such as a botulinum or tetanus toxin, without the toxicity associated with the natural molecule. The polypeptide can also contain a third domain that targets it to a specific cell, rendering the polypeptide useful in inhibition of exocytosis in target cells. Fusion proteins comprising the polypeptide, nucleic acids encoding the polypeptide and methods of making the polypeptide are also provided. Controlled activation of the polypeptide is possible and the polypeptide can be incorporated into vaccines and toxin assays.Type: GrantFiled: January 27, 2009Date of Patent: September 13, 2011Assignees: Syntaxin Limited, The Health Protection AgencyInventors: Clifford Charles Shone, Conrad Padraig Quinn, Keith Alan Foster, John Chaddock, Philip Marks, John Sutton, Patrick Stancombe, Jonathan Wayne
-
Patent number: 8012491Abstract: A single polypeptide is provided which comprises first and second domains. The first domain enables the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis, and the second domain enables the polypeptide to be translocated into a target cell or increases the solubility of the polypeptide, or both. The polypeptide thus combines useful properties of a clostridial toxin, such as a botulinum or tetanus toxin, without the toxicity associated with the natural molecule. The polypeptide can also contain a third domain that targets it to a specific cell, rendering the polypeptide useful in inhibition of exocytosis in target cells. Fusion proteins comprising the polypeptide, nucleic acids encoding the polypeptide and methods of making the polypeptide are also provided. Controlled activation of the polypeptide is possible and the polypeptide can be incorporated into vaccines and toxin assays.Type: GrantFiled: February 11, 2009Date of Patent: September 6, 2011Assignees: Syntaxin, Ltd., Health Protection AgencyInventors: Clifford Charles Shone, Conrad Padraig Quinn, Keith Alan Foster, John Chaddock, Philip Marks, J. Mark Sutton, Patrick Stancombe, Jonathan Wayne
-
Patent number: 8007803Abstract: The present invention provides isolated polypeptides isolatable from a Staphylococcus spp. Also provided by the present invention are compositions that include one or more of the polypeptides, and methods for making and methods for using the polypeptides.Type: GrantFiled: September 11, 2006Date of Patent: August 30, 2011Assignee: Epitopix, LLCInventors: Daryll A. Emery, Darren E. Straub, Laura Wonderling, Lisa L. Herron Olson
-
Patent number: 8007811Abstract: The present invention provides isolated polypeptides isolatable from a Staphylococcus spp. Also provided by the present invention are compositions that include one or more of the polypeptides, and methods for making and methods for using the polypeptides.Type: GrantFiled: February 14, 2006Date of Patent: August 30, 2011Assignee: Epitopix, LLCInventors: Daryll A. Emery, Darren E. Straub, Laura Wonderling, Lisa L. Herron Olson
-
Patent number: 8007812Abstract: The use of flagellin and flagellin related polypeptides for the protection of mammals from the effects of apoptosis is described.Type: GrantFiled: December 22, 2005Date of Patent: August 30, 2011Assignee: Cleveland Clinic FoundationInventors: Andrei V. Gudkov, Joseph A. DiDonato, Vadim Krivokrysenko
-
Patent number: 7988979Abstract: The invention provides proteins from Neisseria meningitidis, including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics.Type: GrantFiled: January 11, 2008Date of Patent: August 2, 2011Assignees: J. Craig Venter Institute, Inc., Novartis AGInventors: Claire M. Fraser, Cesira Galeotti, Guido Grandi, Erin Hickey, Vega Masignani, Maria Rosa Mora, Jeremy Petersen, Mariagrazia Pizza, Rino Rappuoli, Giulo Ratti, Vincenzo Scarlato, Maria Scarselli, Herve Tettelin, Craig Venter
-
Patent number: 7964559Abstract: The present invention relates, e.g., to an isolated polypeptide from a cyanobacterium, Microcystis viridis, which binds specifically to an oligosaccharide comprising the tetrasaccharide Man-alpha-(1?6)Man-beta (1?4) GlcNAc-beta(1?4)GlcNAc. The polypeptide can be obtained, for example, from a cell that expresses a recombinant nucleic acid that encodes a MVL-like polypeptide. The invention also relates to an isolated polypeptide comprising one or more copies of the sequence GPLWSNXEAQXXGPX (SEQ ID NO: 1) and/or one or more copies of the sequence FTGQWXTXVEXXMSV (SEQ ID NO: 2), wherein the polypeptide binds specifically to the above-mentioned oligosaccharide. Conjugates comprising such polypeptides and an effector molecule are also disclosed, as are methods of using such polypeptides or conjugates, e.g., for inhibiting infection by a virus, such as HIV, or for removing a virus, such as HIV, from a sample, such as a bodily fluid or an inanimate object.Type: GrantFiled: March 9, 2005Date of Patent: June 21, 2011Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventor: Carole A. Bewley
-
Patent number: 7919104Abstract: Provided is a P4 peptide, which contains functional epitopes of the PsaA protein of Streptococcus pneumoniae, and related methods and compositions. P4 peptide mimetics having a conformational structure identical or similar to the conformation of P4 (e.g., SEQ ID NO: 1 and SEQ ID NO:2) are provided. An antibody that specifically binds to the epitope defined by the disclosed peptides is provided. A P4-specific antibody is PsaA-specific since P4 defines an epitope specific for PsaA. Immunogenic compositions comprising the peptide of SEQ ID NO: 1 and a pharmaceutical carrier or the peptide of SEQ ID NO:2 and a pharmaceutical carrier are also provided. Methods of using the peptides and antibodies of the invention are provided.Type: GrantFiled: July 29, 2005Date of Patent: April 5, 2011Assignee: The United States of America as represented by the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Edwin W. Ades, Jacquelyn S. Sampson, Sandra Steiner, George M. Carlone, Joseph J. Caba, GowriSankar Rajam
-
Patent number: 7897158Abstract: A single polypeptide is provided which comprises first and second domains. The first domain enables the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis, and the second domain enables the polypeptide to be translocated into a target cell or increases the solubility of the polypeptide, or both. The polypeptide thus combines useful properties of a clostridial toxin, such as a botulinum or tetanus toxin, without the toxicity associated with the natural molecule. The polypeptide can also contain a third domain that targets it to a specific cell, rendering the polypeptide useful in inhibition of exocytosis in target cells. Fusion proteins comprising the polypeptide, nucleic acids encoding the polypeptide and methods of making the polypeptide are also provided. Controlled activation of the polypeptide is possible and the polypeptide can be incorporated into vaccines and toxin assays.Type: GrantFiled: March 14, 2007Date of Patent: March 1, 2011Assignee: Syntaxin, LtdInventors: Clifford Charles Shone, Conrad Padraig Quinn, Keith Alan Foster, John Chaddock, Philip Marks, J. Mark Sutton, Patrick Stancombe, Jonathan Wayne
-
Patent number: 7871628Abstract: The present invention relates to peptide mimics of a conserved gonococcal epitope of Neisseria gonorrhoeae, which epitope is not found on human blood group antigens. This invention also relates to methods and compositions using such peptide mimics for the prophylaxis of gonorrheal infections.Type: GrantFiled: February 26, 2007Date of Patent: January 18, 2011Assignee: University of MassachusettsInventors: Peter A. Rice, Jutamas Ngampasutadol, Sunita Gulati
-
Patent number: 7867498Abstract: The invention relates to polypeptide carrier proteins that comprise at least five CD4+ T cell epitopes, for conjugation to capsular polysaccharides. The carrier proteins are useful as components of vaccines that can elicit a T-cell dependent immune response. These vaccines are particularly useful to confer protection against infection from encapsulated bacteria in infants between the ages of 3 months and about 2 years.Type: GrantFiled: March 25, 2009Date of Patent: January 11, 2011Assignee: Novartis AGInventors: Rino Rappuoli, Guido Grandi
-
Patent number: 7838015Abstract: A combination of CpG oligonucleotides and polymer microparticles is an extremely effective adjuvant for Neisserial antigens. The invention therefore provides a composition comprising: (a) a Neisserial antigen; (b) a CpG oligonucleotide; and (c) a biodegradable polymer microparticle.Type: GrantFiled: October 3, 2002Date of Patent: November 23, 2010Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Derek O'Hagan, Nicholas Valiante
-
Patent number: 7834158Abstract: The present invention relates to an immunoglobulin-binding protein, wherein at least one asparagine residue has been mutated to an amino acid other than glutamine or aspartic acid, which mutation confers an increased chemical stability at pH-values of up to about 13-14 compared to the parental molecule. The protein can for example be derived from a protein capable of binding to other regions of the immunoglobulin molecule than the complementarity determining regions (CDR), such as protein A, and preferably the B-domain of Staphylococcal protein A. The invention also relates to a matrix for affinity separation, which comprises an immunoglobulin-binding protein as ligand coupled to a solid support, in which protein ligand at least one asparagine residue has been mutated to an amino acid other than glutamine.Type: GrantFiled: March 20, 2003Date of Patent: November 16, 2010Assignee: GE Healthcare Bio-Sciences ABInventor: Sophia Hober
-
Patent number: 7816494Abstract: An isolated extracellular matrix-binding protein, designated as SdrC and its corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection. In particular, the proteins or antibodies thereof may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of S. aureus to wounds or biomaterials.Type: GrantFiled: August 24, 2009Date of Patent: October 19, 2010Assignee: The Texas A&M University SystemInventors: Joseph M. Patti, Timothy J. Foster, Elizabet Joseffson, Deidre Ni Eidhin, Magnus A. O. Hook, Samuel E. Perkins
-
Patent number: 7807184Abstract: The present invention relates to a hybrid bacterial toxin subunit, to a hybrid bipartite bacterial toxin and to nucleic acid molecules comprising a nucleotide sequence encoding such bacterial toxins. Furthermore, the invention relates to vaccines comprising bacterial toxins and to their use in vaccines. Finally, the invention relates to methods for the preparation of such vaccines and to the use of such bacterial toxins for the manufacture of such vaccines.Type: GrantFiled: July 16, 2004Date of Patent: October 5, 2010Assignee: Interuet International B.V.Inventor: Paul Vermeij
-
Patent number: 7794734Abstract: Vaccine preparations for the prevention and treatment of bovine respiratory disease (BRD) and, in particular, its most severe form, termed “shipping fever”, are provided. The preparations comprise chimeric proteins comprising immunodominant epitopes of recombinant Mannheimia haemolytica outer membrane protein PlpE, and immunodominant epitopes of recombinant M. haemolytica leukotoxin.Type: GrantFiled: October 6, 2006Date of Patent: September 14, 2010Assignee: The Board of Regents for Oklahoma State UniversityInventors: Sahlu Ayalew, Anthony W. Confer
-
Patent number: 7794733Abstract: Nucleic acid and amino acid sequences of the Omp85 proteins of N. gonorrhoeae and N. meningitidis, and fragments thereof are useful in vaccine compositions, therapeutic compositions and diagnostic compositions for use in the prevention, treatment and diagnosis of non-symptomatic gonococcal infection or symptomatic disease and non-symptomatic meningococcal infection and symptomatic disease. Antibodies are developed to these proteins and also useful in the compositions and methods described herein.Type: GrantFiled: June 26, 2003Date of Patent: September 14, 2010Assignee: The University of MontanaInventors: Ralph C. Judd, D. Scott Manning
-
Patent number: 7794731Abstract: The invention provides a fusion protein comprising a flagellin adjuvant and a Yersinia pestis antigen. Also provided are compositions comprising a flagellin adjuvant and a Yersinia pestis antigen. The invention also discloses methods of making a fusion protein comprising a flagellin adjuvant and a Yersinia pestis antigen. The invention further provides pharmaceutical formulations and methods for inducing an immune response against Yersinia pestis.Type: GrantFiled: December 16, 2005Date of Patent: September 14, 2010Assignee: Wake Forest University Health SciencesInventors: Steven B. Mizel, Anna Nichole Honko
-
Patent number: 7790845Abstract: The present invention relates to a functionally expressed bacterial voltage-sensitive ion-selective channel. The novel channel can be used in conjunction with mammalian ion channel pore-containing regions in assays for screening for compounds that modulate activity of the channel. One bacterial ion channel of the present invention, called NaChBac, is derived from Bacillus halodurans (GenBank#BAB05220 (8)).Type: GrantFiled: November 5, 2002Date of Patent: September 7, 2010Assignee: Children's Medical Center CorporationInventors: David Clapham, Dejian Ren
-
Patent number: 7785608Abstract: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.Type: GrantFiled: September 2, 2003Date of Patent: August 31, 2010Assignee: Wyeth Holdings CorporationInventors: Gary W. Zlotnick, Leah Diane Fletcher, John Erwin Farley, Liesel A. Bernfield, Robert J. Zagursky, Benjamin J. Metcalf
-
Patent number: 7759094Abstract: The invention relates to a method for the production of L-amino acids by fermentation of recombinant microorganisms of the Enterobacteriaceae family, characterized in that a) the microorganisms producing the desired L-amino acid and wherein the lamB-gene or nucleotide sequence coding for the gene product maltoporin is amplified, particularly overexpressed, are cultivated in a medium in conditions enabling the desired L-amino acid to be enriched in the medium or in cells, and b) the desired L-amino acid is isolated, wherein constituents of the fermentation broth and/or biomass remain in the entirety thereof or in parts thereof (=0 bis 100%) in the isolated product or are fully removed.Type: GrantFiled: July 5, 2005Date of Patent: July 20, 2010Assignee: Degussa GmbHInventor: Mechthild Rieping
-
Patent number: 7754224Abstract: Sequences encoding two immunoreactive glycoproteins were cloned from Ehrlichia canis (p153 gene) and Ehrlichia chaffeensis (p156 gene). These two glycoproteins are species-specific immunoreactive orthologs that are useful as subunit vaccines and for serologic and molecular diagnostics for E. canis and E. chaffeensis.Type: GrantFiled: March 12, 2007Date of Patent: July 13, 2010Assignee: Research Development FoundationInventors: Jere W. McBride, David H. Walker
-
Patent number: 7749516Abstract: The GapC plasmin binding protein genes of Streptococcus dysgalactiae (S. dysgalactiae), Streptococcus agalactiae (S. agalactiae), Streptococcus uberis (S. uberis), Streptococcus parauberis (S. parauberis), and Streptococcus iniae (S. iniae) are described, as well as the recombinant production of the GapC proteins therefrom. Also described is the use of the GapC proteins from those species in vaccine compositions to prevent or treat bacterial infections in general, and mastitis in particular.Type: GrantFiled: August 13, 2007Date of Patent: July 6, 2010Assignee: University of SaskatchewanInventors: Alexandra J Bolton, Jose Perez-Casal, Michael Fontaine, Andrew A Potter
-
Patent number: 7723480Abstract: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the structural modification. The structural modification includes addition or deletion of a leucine-based motif or parts thereof. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat biological disorders include treating autonomic disorders, neuromuscular disorders or pains.Type: GrantFiled: March 26, 2008Date of Patent: May 25, 2010Assignee: Allergan, Inc.Inventors: Lance E. Steward, Todd M. Herrington, Kei Roger Aoki
-
Patent number: 7705125Abstract: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the structural modification. The structural modification includes addition or deletion of a leucine-based motif or parts thereof. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat biological disorders include treating autonomic disorders, neuromuscular disorders or pains.Type: GrantFiled: March 27, 2008Date of Patent: April 27, 2010Assignee: Allergan, Inc.Inventors: Lance E. Steward, Todd M. Herrington, Kei Roger Aoki
-
Patent number: 7705124Abstract: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the structural modification. The structural modification includes addition or deletion of a leucine-based motif or parts thereof. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat biological disorders include treating autonomic disorders, neuromuscular disorders or pains.Type: GrantFiled: March 24, 2008Date of Patent: April 27, 2010Assignee: Allergan, Inc.Inventors: Lance E. Steward, Todd M. Herrington, Kei Roger Aoki
-
Patent number: 7691974Abstract: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the structural modification. The structural modification includes addition or deletion of a leucine-based motif or parts thereof. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat biological disorders include treating autonomic disorders, neuromuscular disorders or pains.Type: GrantFiled: March 25, 2008Date of Patent: April 6, 2010Assignee: Allergan, Inc.Inventors: Lance E. Steward, Todd M. Herrington, Kei Roger Aoki
-
Patent number: 7691983Abstract: The present invention relates to a toxin comprising a modified light chain of a botulinum toxin type E, wherein the modified light chain comprises amino acid sequence PFVNKQFN (SEQ ID NO: 120) at the N-terminus, and amino acid sequence xExxxLL (SEQ ID NO: 112) at the C-terminus, wherein x is any amino acid.Type: GrantFiled: January 14, 2005Date of Patent: April 6, 2010Assignee: Allergan, Inc.Inventors: Ester Fernandez-Salas, Lance E. Steward, Todd Herrington, K. Roger Aoki
-
Patent number: 7678379Abstract: The invention provides novel Class I HLA-A2 and Class II HLA-DR4-restricted epitopes and methods for their use in detecting T-cells in peripheral blood specific for infection or latency of mycobacterial infection, including M. tuberculosis and M. leprae as others. For example, methods for diagnosing the presence of infection or exposure by M. tuberculosis utilize multimers of HLA monomers or modified monomers having a bound HLA-binding peptide to perform high throughput screening of patient PBLs. The methods can be used for monitoring the success of anti mycobacterial treatment in patients and to screen vaccines and drugs for effectiveness in treating or preventing exposure, infection and latency of mycobacteria in humans.Type: GrantFiled: June 17, 2005Date of Patent: March 16, 2010Assignee: Beckman Coulter, Inc.Inventor: Markus Joseph Maeurer
-
Patent number: 7674470Abstract: Antigenic compositions are provided comprising a single chain polypeptide comprising first and second domains, wherein said first domain is a clostridial neurotoxin light chain or a fragment or a variant thereof and is capable of cleaving one or more vesicle or plasma membrane associated proteins essential to exocytosis; and said second domain is a clostridial neurotoxin heavy chain HN portion or a fragment or a variant thereof, wherein said second domain is capable of (i) translocating the polypeptide into a cell or (ii) increasing the solubility of the polypeptide compared to the solubility of the first domain on its own or (iii) both translocating the polypeptide into a cell and increasing the solubility of the polypeptide compared to the solubility of the first domain on its own; and wherein the second domain lacks a functional C-terminal part of a clostridial neurotoxin heavy chain designated HC thereby rendering the polypeptide incapable of binding to cell surface receptors that are the natural cell surType: GrantFiled: March 11, 2005Date of Patent: March 9, 2010Assignees: Health Protection Agency, Syntaxin LimitedInventors: Charles Clifford Shone, Conrad Padraig Quinn, Keith Alan Foster, John Chaddock, Philip Marks, J. Mark Sutton, Patrick Stancombe, Jonathan Wayne
-
Patent number: 7671177Abstract: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the structural modification. The structural modification includes addition or deletion of a leucine-based motif or parts thereof. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat biological disorders include treating autonomic disorders, neuromuscular disorders or pains.Type: GrantFiled: March 28, 2008Date of Patent: March 2, 2010Assignee: Allergan, Inc.Inventors: Lance E. Steward, Todd M. Herrington, Kei Roger Aoki
-
Patent number: 7638130Abstract: A recombinant, refolded non-fusion polypeptide expressed from a truncated r56 gene of the causative agent of scrub typhus, Orientia tsutsugamushi for the Karp, Kato and Gilliam strains has been produced. The invention is useful for detecting prior exposure to scrub typhus, screening for and/or identification of at least one infectious strain-similarity (i.e. a Karp-like, Kato-like or Gilliam-like strain) based on its strength of reaction toward a truncated protein and as a component in vaccine formulation sand production of immune globulins for passive prophylaxis and immunity in subjects.Type: GrantFiled: December 27, 2007Date of Patent: December 29, 2009Assignee: The United States of America as represented by the Secretary of the NavyInventors: Wei-Mei Ching, Daryl J. Kelly, Gregory A. Dasch
-
Patent number: 7635480Abstract: The present invention provides a compound chosen from: a peptide represented by the sequence SEQ ID No: 1 below: SEQ ID No: 1 Lys-Ala-Lys-Pro-Val-Gln-Lys-Leu-Asp-Asp-Asp-Asp-Asp-Gly-Asp-Asp-Thr-Tyr-Lys-Glu-Glu-Arg-His-Asn-Lys and homologs of this peptide exhibiting at least 80% similarity with the sequence SEQ ID No: 1 and comprising from 20 to 30 amino acids. These compounds are useful in preventing, diagnosing and treating animal and/or human leptospirosis.Type: GrantFiled: October 24, 2003Date of Patent: December 22, 2009Assignee: Virbac S.A.Inventors: Geneviève Andre-Fontaine, Benoît Chatrenet, Christine Branger, André Aubert
-
Patent number: 7635483Abstract: Novel vaccines for use against ?-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of streptococcal C5a peptidase (SCP). Also disclosed is a method of protecting a susceptible mammal against ?-hemolytic Streptococcus colonization or infection by administering such a vaccine. Enzymatically inactive SCP, and polynucleotides encoding these SCP proteins are further disclosed.Type: GrantFiled: August 10, 2004Date of Patent: December 22, 2009Assignee: Regents of the University of MinnesotaInventors: Paul Patrick Cleary, Deborah K. Stafslien
-
Patent number: 7618636Abstract: WO99/36544 discloses a large number of proteins from Neisseria Meningitidis. The present invention relates to fragments of those proteins which comprise at least one antigenic determinant. Homologous sequences and proteins comprising these fragments are also disclosed.Type: GrantFiled: July 13, 2000Date of Patent: November 17, 2009Assignee: Novartis Vaccines And Diagnostics SRLInventors: Vega Masignani, Vincenzo Scarlato, Maria Scarselli, Cesira L. Galeotti, Marirosa Mora
-
Patent number: 7585944Abstract: The subject invention relates to novel Xenorhabdus toxin complex (TC) proteins and genes that encode these proteins. More specifically, the subject invention relates to TC genes and proteins obtainable from Xenorhabdus bovienii strain ILM104.Type: GrantFiled: September 18, 2007Date of Patent: September 8, 2009Assignee: Dow Agrosciences LLCInventors: Patricia C. Apel-Birkhold, Timothy D. Hey, Joel J. Sheets, Thomas Meade, Ze-Sheng Li, Justin M. Lira, Sean M. Russell, Robin L. Thompson, Jon C. Mitchell, Kristin Fencil
-
Patent number: 7576176Abstract: The invention provides proteins from Neisseria meningitidis, including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics.Type: GrantFiled: April 30, 1999Date of Patent: August 18, 2009Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Claire Fraser, Cesira Galeotti, Guido Grandi, Erin Hickey, Vega Masignani, Marirosa Mora, Jeremy Petersen, Mariagrazia Pizza, Rino Rappuoli, Giulio Ratti, Vincenzo Scarlato, Maria Scarselli, Herve Tettelin, J. Craig Venter
-
Patent number: 7550426Abstract: A class of procytotoxic agents is characterized by a capability to kill with target cell-specificity. Such an aspect can be a pore-forming protein which has at least one lysine residue, modified by a peptide linkage to an amino acid residue, via the epsilon amino group, and an acetyl group. These agents are useful in treating cancer, especially prostate cancer.Type: GrantFiled: May 18, 2005Date of Patent: June 23, 2009Assignee: GHC Research Development CorporationInventors: Thomas E. Wagner, Xianzhong Yu
-
Patent number: 7534444Abstract: Molecular mimetics of a surface-exposed epitope on loop 4 of PorA of Neisseria meningitidis serogroup B (MenB) P1.2 serosubtype and antibodies produced against the same are disclosed. Compositions containing such molecular mimetics or the antibodies thereto can be used to prevent MenB disease, as well as for diagnosis of MenB infection.Type: GrantFiled: April 11, 2002Date of Patent: May 19, 2009Assignee: Novattis Vaccines and Diagnostics, Inc.Inventors: Dan M. Granoff, Gregory Moe, Rino Rappuoli
-
Patent number: 7531176Abstract: The invention relates to Brachyspira pilosicoli 72 kDa outer-membrane protein (Bpmp-72) and its amino acid and nucleotide sequence. The invention also relates to the uses of these sequences in prophylactic (vaccination) and therapeutic treatment of infections with Brachyspira pilosicoli (internal spirochaetosis).Type: GrantFiled: December 17, 2004Date of Patent: May 12, 2009Inventors: David J Hampson, Tom La
-
Patent number: 7517955Abstract: A polypeptide, designated as “Streptococcus uberis Adhesion Molecule” (SUAM), and fragments of SUAM, prevent internalization and adherence of Streptococcus uberis and other streptococcal pathogens to cells. The SUAM polypeptide and fragments may be used diagnostically and therapeutically. Nucleic acid sequences encoding the SUAM polypeptide and fragments are included in the invention.Type: GrantFiled: October 22, 2003Date of Patent: April 14, 2009Assignee: University of Tennessee Research FoundationInventors: Stephen P. Oliver, Raul A. Almeida, Douglas A. Luther, Hee-Myung Park